After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Google Research on November 7, 2025, introduced a new machine learning paradigm called Nested Learning, designed to solve catastrophic forgetting in AI models. This long-standing problem causes models ...

Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...

Wild orangutans use multi-layered recursive vocal patterns that vary with danger, challenging the idea that only humans use complex, structured communication. In a groundbreaking study from the ...

On the server I am running, I noticed a lot of lag coming from some of the refined storage exporters with autocrafting upgrades. I ran observable sampler over it and ...

Recursion Pharma RXRX shares have plunged 37.1% in the past month compared with the industry’s 1.4% decline. The company has also underperformed in the sector and the S&P 500 during the same time ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage ...